



Patented
Medicine Prices
Review Board

Conseil d'examen
du prix des médicaments
brevetés



Alignment of Oncology Drug Coverage Across Canada

May 28, 2019

Presented by: Nevzeta Bosnic, Senior Economist

*NPDUIS, Policy and Economic Analysis Branch
Patented Medicine Prices Review Board*

Canada



Background and Objectives

- Understanding the current drug coverage is the key to the development of a national pharmacare program in Canada
- This study analyzes the current coverage of oncology medicines and identifies the level of congruence across Canadian public drug plans
 - These preliminary findings will form the basis of a more comprehensive study on oncology medicine coverage to be published as the second part of the PMPRB's *Formularies in Canada* series
 - This information will inform the dialogue on the affordability and accessibility of oncology medicines, including discussions around the development of a national formulary



Methods

➤ Drug Selection

- Includes 85 medicines reviewed by the interim Joint Oncology Drug Review (iJODR) and the pan-Canadian Oncology Drug Review (pCODR) from March 1, 2007, through June 30, 2018
- Analyzed at the medicinal ingredient level, irrespective of indication

➤ Data

- pCODR and other publically available data on drug listings
- IQVIA, Canadian Drugstore and Hospital Purchases Audit (CDH)
- IQVIA, Private Drug Plan database

➤ Data Analysis

- Percentage of the selected medicines that are listed in public drug programs (including Quebec) and Canadian private drug plans, as of December 31, 2018
- Weighted listing rates based on Canadian national retail and hospital sales in 2018
- Average bilateral rates of agreement across all provinces using a paired approach



Considerations

- **Variation in the coverage of medicines** across public plans may be impacted by differences in the plan designs, demographics, and the disease profiles of the eligible beneficiary populations.
- **Sales weights** are based on overall national retail and hospital sales. Medicines not commonly reimbursed, or reimbursed by smaller plans, may have lower related sales, and hence, lower weights in the overall results.
- **Sales data** for some of the selected medicines is not available in the IQVIA CDH database; this may have a slight impact on some of the results.




Key Findings

1. The coverage of oncology medicines is relatively high in public drug programs in Canada
2. Most of selected oncology medicines were listed in 6 or more public drug programs
3. Provinces have a relatively high rate of congruence in coverage of oncology medicines
4. There are some variations in spending on oncology medicines across provinces



The coverage of oncology medicines is relatively high in public drug programs in Canada

Selected oncology drugs 2018, n=85



Data source: Publically available data including the pCODR and INESSS websites; IQVIA Private Drug Plan database; IQVIA Canadian Drugstore and Hospital Purchases Audit (CDH) database.







Most of the selected oncology medicines were listed in 6 or more public drug programs

Selected oncology drugs 2018, n=85

Distribution of oncology medicine coverage




Data source: Publically available data including the pCODR and INESSS websites; IQVIA Private Drug Plan database; IQVIA Canadian Drugstore and Hospital Purchases Audit (CDH) database.





Provinces have a relatively high rate of congruence in coverage of oncology medicines




Selected oncology drugs 2018, n=85

	Average	Median	Minimum	Maximum	Standard deviation
Agreement rate	90%	91%	74%	99%	5%
Sales-weighted agreement rate	95%	97%	84%	100%	5%

Data source: Publically available data including the pCODR and INESSS websites; IQVIA Private Drug Plan database; IQVIA Canadian Drugstore and Hospital Purchases Audit (CDH) database.

There are some variations in spending on oncology medicines across provinces

Selected medicine sales per 100,000 population




Note: The results include both public (including hospitals) and private (including cash) sales.

Data source: IQVIA Canadian Drugstore and Hospital Purchases Audit (CDH) database.

There are some variations in spending on oncology medicines across provinces

Shares of total pharmaceutical market



Data source: IQVIA Canadian Drugstore and Hospital Purchases Audit (CDH) database.



Patented
Medicine Prices
Review Board

Conseil d'examen
du prix des médicaments
brevetés

Expected release of the report:
End of 2019/20 fiscal year



National Prescription Drug Utilization Information System

THANK YOU

Patented Medicine Prices Review Board

Canada 